| 摘要 |
Human or murine MIA-2 (melanoma-inhibiting activity-2) proteins (A) that are encoded, respectively, by sequences (1) and (27), comprising 1626 and 1628 bp, and their variants having one or more substitutions, insertions and/or deletions, are new. Human or murine MIA-2 (melanoma-inhibiting activity-2) proteins (A) that are encoded, respectively, by sequences (1) and (27), of 1626 and 1628 bp, and their variants having one or more substitutions, insertions and/or deletions are new. The variants (a) hybridize under moderately stringent conditions to (1) or (27) and encode proteins with MIA-2 activity or (b) are degenerate within the scope of the genetic code and encode the same proteins as (1) and (27) or their functional equivalents. (A) are not encoded exclusively by bases 1-354 of (1) or 1-357 of (27), or their fragments. Independent claims are also included for the following: (1) isolated (1) and (27) and their variants, as specified above; (2) the MIA-2 promoter, comprising a 3090 bp sequence (human) reproduced; (3) nucleic acid (NA1) that (i) is a transcription product (TP) of the nucleic acids (NA2) of items (1) and (2) or (ii) can bind selectively under moderately stringent conditions to TP, particularly antisense RNA or DNA; (4) DNA or RNA probes that hybridize to NA2; (5) vector that includes NA1 or NA2; (6) host cell transformed with the vector of (5); (7) antibody or aptamer against an epitope of (A); (8) transgenic mammal in which the MIA-2 sequence is inactivated, preferably conditionally or in which the genome contains one or more NA2; (9) ex vivo methods for diagnosing liver damage, for detecting increased synthetic capacity of the liver or for detecting the acute phase of an infection, inflammatory or rheumatic disease; (10) preparing an organ culture by contacting mammalian hepatocytes with MIA-2 protein; and (11) organ cultures produced by method (10). |
